Scoop: Med­Im­mune chief Bahi­ja Jal­lal is leav­ing As­traZeneca and join­ing the trek in­to biotech

Six years af­ter As­traZeneca’s then new CEO Pas­cal So­ri­ot named Bahi­ja Jal­lal pres­i­dent of the big Med­Im­mune sub­sidiary in Gaithers­burg, MD, putting her at the cen­ter of the com­pa­ny’s R&D turn­around plans, the long­time phar­ma ex­ec is join­ing the great mi­gra­tion of in­dus­try pro­fes­sion­als to biotech.

Eliot Forster

Jal­lal is tak­ing the helm at Im­muno­core next week, a promi­nent TCR play­er in the UK which has been go­ing through a re­mark­able shake­up af­ter the orig­i­nal team un­der CEO Eliot Forster — now chief at F-star — ei­ther left or were forced out. Im­muno­core was able to raise $320 mil­lion a lit­tle more than 3 years ago — a time when that kind of mon­ey was still able to cause as­ton­ish­ment in the in­dus­try.

This wasn’t the first such biotech job to come along, Jal­lal tells me in an ex­clu­sive in­ter­view ahead of the an­nounce­ment. “But when the right one is there you jump on it.”

The job starts on Mon­day, and Jal­lal says she feels like “a kid in a can­dy store” when it comes to Im­muno­core, a com­pa­ny with a broad plat­form that is built to ac­com­mo­date on­col­o­gy as well as in­fec­tious dis­eases and au­toim­mune con­di­tions.

And Jal­lal isn’t the on­ly se­nior As­traZeneca ex­ec head­ing to new biotech fields. The Wall Street Jour­nal re­ports to­day that Mark Mal­lon — cur­rent EVP in charge of port­fo­lio strat­e­gy — is on his way to take the CEO job at Iron­wood, as that com­pa­ny splits up un­der pres­sure and Pe­ter Hecht leaves to run the R&D spin­out.

An­drew Hotchkiss

Over the past year-plus Im­muno­core has run in­to some se­vere tur­bu­lence af­ter it tried to shop a new round at its old uni­corn val­u­a­tion. Po­ten­tial in­vestors weren’t ready to buy in, trig­ger­ing an ex­o­dus at the top and a move up for chief com­mer­cial of­fi­cer An­drew Hotchkiss as in­ter­im chief.

Jal­lal says Hotchkiss has done a great job this year, which in­cludes ink­ing a ma­jor new pact with Genen­tech, and he’ll go back to con­cen­trat­ing on his com­mer­cial fo­cus with an eye on ad­vanc­ing Im­muno­core’s late-stage can­cer ther­a­py to­ward the mar­ket.

“I can tell you there’s been a lot of progress in the past year,” she adds. “Next week we’re go­ing to JP­Mor­gan and share the sto­ry with the in­vestor com­mu­ni­ty and oth­ers. My in­ten­tion is to bring re­as­sur­ance to in­vestors that I will bring sta­bil­i­ty to the or­ga­ni­za­tion, bring the best team and have the vi­sion we can all work to­geth­er and show them why I am join­ing the com­pa­ny.”

Mene Pan­ga­los

Jal­lal was one of three top R&D ex­ecs So­ri­ot picked for the Big Phar­ma’s turn­around in 2013. Brig­gs Mor­ri­son left sev­er­al years ago to run Syn­dax. That leaves Mene Pan­ga­los and his new col­leagues to run the show at As­traZeneca’s re­search and de­vel­op­ment op­er­a­tions.

There’s no im­me­di­ate word on who will re­place Jal­lal at Med­im­mune, where she steered 5 drugs to an ap­proval, in­clud­ing their check­point play­er Imfinzi.


Im­age: Bahi­ja Jal­lal. MED­IM­MUNE

ZS Per­spec­tive: 3 Pre­dic­tions on the Fu­ture of Cell & Gene Ther­a­pies

The field of cell and gene therapies (C&GTs) has seen a renaissance, with first generation commercial therapies such as Kymriah, Yescarta, and Luxturna laying the groundwork for an incoming wave of potentially transformative C&GTs that aim to address diverse disease areas. With this renaissance comes several potential opportunities, of which we discuss three predictions below.

Allogenic Natural Killer (NK) Cells have the potential to displace current Cell Therapies in oncology if proven durable.

Despite being early in development, Allogenic NKs are proving to be an attractive new treatment paradigm in oncology. The question of durability of response with allogenic therapies is still an unknown. Fate Therapeutics’ recent phase 1 data for FT516 showed relatively quicker relapses vs already approved autologous CAR-Ts. However, other manufacturers, like Allogene for their allogenic CAR-T therapy ALLO-501A, are exploring novel lymphodepletion approaches to improve persistence of allogenic cells. Nevertheless, allogenic NKs demonstrate a strong value proposition relative to their T cell counterparts due to comparable response rates (so far) combined with the added advantage of a significantly safer AE profile. Specifically, little to no risk of graft versus host disease (GvHD), cytotoxic release syndrome (CRS), and neurotoxicity (NT) have been seen so far with allogenic NK cells (Fig. 1). In addition, being able to harness an allogenic cell source gives way to operational advantages as “off-the-shelf” products provide improved turnaround time (TAT), scalability, and potentially reduced cost. NKs are currently in development for a variety of overlapping hematological indications with chimeric antigen receptor T cells (CAR-Ts) today, and the question remains to what extent they will disrupt the current cell therapy landscape. Click for more details.

Graphic: Kathy Wong for Endpoints News

What kind of biotech start­up wins a $3B syn­di­cate, woos a gallery of mar­quee sci­en­tists and re­cruits GSK's Hal Bar­ron as CEO in a stun­ner? Let Rick Klaus­ner ex­plain

It started with a question about a lifetime’s dream on a walk with tech investor Yuri Milner.

At the beginning of the great pandemic, former NCI chief and inveterate biotech entrepreneur Rick Klausner and the Facebook billionaire would traipse Los Altos Hills in Silicon Valley Saturday mornings and talk about ideas.

Milner’s question on one of those mornings on foot: “What do you want to do?”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Hal Barron (GSK via YouTube)

GSK R&D chief Hal Bar­ron jumps ship to run a $3B biotech start­up, Tony Wood tapped to re­place him

In a stunning switch, GlaxoSmithKline put out word early Wednesday that R&D chief Hal Barron is exiting the company after 4 years — a relatively brief run for the man chosen by CEO Emma Walmsley in late 2017 to turn around the slow-footed pharma giant.

Barron is being replaced by Tony Wood, a close associate of Barron’s who’s taking one of the top jobs in Big Pharma R&D. He’ll be closer to home, though, for GSK. Barron has been running a UK and Philadelphia-based research organization from his perch in San Francisco.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.

FDA+ roundup: FDA's neu­ro­science deputy de­parts amid on­go­ing Aduhelm in­ves­ti­ga­tions; Califf on the ropes?

Amid increased scrutiny into the close ties between FDA and Biogen prior to the controversial accelerated approval of Aduhelm, the deputy director of the FDA’s office of neuroscience has called it quits after more than two decades at the agency.

Eric Bastings will now take over as VP of development strategy at Ionis Pharmaceuticals, the company said Wednesday, where he will provide senior clinical and regulatory leadership in support of Ionis’ pipeline.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Sec­ondary patents prove to be key in biosim­i­lar block­ing strate­gies, re­searchers find

While the US biosimilars industry has generally been a disappointment since its inception, with FDA approving 33 biosimilars since 2015, just a fraction of those have immediately followed their approvals with launches. And more than a handful of biosimilars for two of the biggest blockbusters of all time — AbbVie’s Humira and Amgen’s Enbrel — remain approved by FDA but still have not launched because of legal settlements.

Chamath Palihapitiya and Pablo Legorreta

Bil­lion­aires Chamath Pal­i­hapi­tiya and Pablo Legor­re­ta hatch an $825M SPAC for cell ther­a­py biotech

Three years after Royalty Pharma chief Pablo Legorreta led a group of investors to buy up a pair of biotechs and create a new startup called ProKidney, the biotech is jumping straight into an $825 million public shell created by SPAC king and tech billionaire Chamath Palihapitiya.

ProKidney was founded 6 years ago but really got going at the beginning of 2019 with the $62 million acquisition of inRegen, which was working on an autologous — from the patient — cell therapy for kidney disease. After extracting kidney cells from patients, researchers expand the cells in the lab and then inject them back into patients, aiming to restore the kidneys of patients suffering from CKD.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.

CBO: Medicare ne­go­ti­a­tions will ham­per drug de­vel­op­ment more than pre­vi­ous­ly thought

As President Biden’s Build Back Better Act — and, with it, potentially the Democrats’ last shot at major drug pricing reforms in the foreseeable future — remains on life support, the Congressional Budget Office isn’t helping their case.

The CBO last week released a new slide deck, outlining an update to its model on how Medicare negotiations might take a bite out of new drugs making it to market. The new model estimates a 10% long-term reduction in the number of new drugs, whereas a previous CBO report from August estimated that 8% fewer new drugs will enter the market over 30 years.

Joshua Brumm, Dyne Therapeutics CEO

FDA or­ders DMD tri­al halt, rais­ing ques­tions about a whole class of promis­ing drugs

Dyne Therapeutics’ stock took a nasty hit this morning after the biotech put out word that the FDA had slapped a clinical hold on their top program for Duchenne muscular dystrophy. And now speculation is bouncing around Biotwitter that there could be a class effect at work here that would implicate other drug developers in the freeze.

Dyne execs didn’t have a whole lot to say about why the FDA sidelined their IND for DYNE-251 in DMD while “requesting additional clinical and non-clinical information for” the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.

Martin Shkreli (Photo by Drew Angerer/Getty Images)

Mar­tin Shkre­li re­ceives life­time in­dus­try ban, forced to re­turn al­most $65M in prof­its af­ter an­ti­com­pet­i­tive scheme

Martin Shkreli will have to find a new nickname.

A federal judge banned the former biotech CEO and “Pharma Bro” from the drug industry on Friday, ordering him to pay nearly $65 million in illicit profits. Shkreli was convicted of securities fraud in 2017 and is currently serving a seven-year prison sentence, though he originally gained notoriety for raising the price of the antiparasitic drug Daraprim from $13.50 to $750 in 2015.